Literature DB >> 304376

Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue.

W H Isacoff, P F Morrison, J Aroesty, K L Willis, J B Block, T L Lincoln.   

Abstract

The methotrexate (MTX)-plasma concentrations of 172 high-dose infusions over the range of 50-200 mg/kg were measured over the 72-hour period following the beginning of infusion. Pharmacokinetic analysis shows that a biexponential function adequately describes the plasma decay for all doses. The distribution of plasma clearances over the patient population at a given dose has been characterized by a biexponential clearance function and associated time-dependent variance. It is found that when each of the plasma clearance functions are scaled by their respective dose, the 1 SD bands about the resulting unit dose curves overlap throughout their time ranges and are therefore insignificantly different from one another. Thus, the plasma clearance over the 50-200-mg/kg range may be represented by a single dose-scalable biexponential model with half-lives of 1.8 +/- 0.1 and 8.4 +/- 0.5 hours. For a given maximum allowable plasma-MTX level (eg, 10(-5) M at 24 hours), the variance of the clearance distribution is shown to predict the expected fraction of patients who will require intensified rescue. Urinary clearance has been determined at 104 +/- 8 ml/minute over the dose range of 50-300 mg/kg and only 60% of the MTX was excreted in the urine by 72 hours.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 304376

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  22 in total

1.  Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate.

Authors:  Markus Joerger; Andrés J M Ferreri; Stephan Krähenbühl; Jan H M Schellens; Thomas Cerny; Emanuele Zucca; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

2.  Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.

Authors:  W E Evans; C B Pratt; R H Taylor; L F Barker; W R Crom
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits.

Authors:  H Iven; H Brasch; J Engster
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Effect of oral cholestyramine on the elimination of high-dose methotrexate.

Authors:  R Erttmann; G Landbeck
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

5.  The effects of antibiotics and uricosuric drugs on the renal elimination of methotrexate and 7-hydroxymethotrexate in rabbits.

Authors:  H Iven; H Brasch
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  Mathematical modeling -- guide to high-dose methotrexate infusion therapy.

Authors:  S D Reich
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 7.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

8.  Effect of combination chemotherapy, duration of methotrexate administration, and patient's age on methotrexate pharmacokinetics.

Authors:  F Lokiec; O Poirier; C Gisselbrecht; M Marty; M Boiron; Y Najean
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion.

Authors:  M L Chen; W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1983-10

10.  Clinical pharmacokinetics of 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses.

Authors:  M Luyckx; J L Cazin; C Brunet; P Gosselin; M C Demaille
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.